Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $11.98 in the prior trading day, CorMedix Inc (NASDAQ: CRMD) closed at $12.19, up 1.75%. In other words, the price has increased by $1.75 from its previous closing price. On the day, 0.96 million shares were traded. CRMD stock price reached its highest trading level at $12.2403 during the session, while it also had its lowest trading level at $12.0.
Ratios:
Our goal is to gain a better understanding of CRMD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.24 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.91. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.94. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On June 30, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 18 ’25 when Todisco Joseph sold 30,000 shares for $12.00 per share. The transaction valued at 360,000 led to the insider holds 509,496 shares of the business.
Joseph Todisco bought 30,000 shares of CRMD for $359,149 on Dec 18 ’25. On Dec 09 ’25, another insider, Dillione Janet, who serves as the Director of the company, sold 34,000 shares for $12.00 each. As a result, the insider received 408,000 and left with 48,473 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 960438464 and an Enterprise Value of 1053642560. As of this moment, CorMedix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.94, and their Forward P/E ratio for the next fiscal year is 4.80. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.48 while its Price-to-Book (P/B) ratio in mrq is 2.55. Its current Enterprise Value per Revenue stands at 4.917 whereas that against EBITDA is 9.738.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.37, which has changed by 0.4847747 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $17.43, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is 11.23%, while the 200-Day Moving Average is calculated to be 8.51%.
Shares Statistics:
The stock has traded on average 2.73M shares per day over the past 3-months and 2620770 shares per day over the last 10 days, according to various share statistics. A total of 78.35M shares are outstanding, with a floating share count of 69.21M. Insiders hold about 11.89% of the company’s shares, while institutions hold 56.57% stake in the company. Shares short for CRMD as of 1765756800 were 16875402 with a Short Ratio of 6.17, compared to 1763078400 on 17445325. Therefore, it implies a Short% of Shares Outstanding of 16875402 and a Short% of Float of 21.63.
Earnings Estimates
The dynamic stock of CorMedix Inc (CRMD) is currently attracting attention from 2.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.72, with high estimates of $0.72 and low estimates of $0.72.
Analysts are recommending an EPS of between $2.85 and $2.42 for the fiscal current year, implying an average EPS of $2.63. EPS for the following year is $2.5, with 2.0 analysts recommending between $2.53 and $2.47.
Revenue Estimates
7 analysts predict $127.52M in revenue for. The current quarter. It ranges from a high estimate of $135.16M to a low estimate of $120M. As of. The current estimate, CorMedix Inc’s year-ago sales were $31.21MFor the next quarter, 7 analysts are estimating revenue of $127.41M. There is a high estimate of $127.41M for the next quarter, whereas the lowest estimate is $127.41M.
A total of 7 analysts have provided revenue estimates for CRMD’s current fiscal year. The highest revenue estimate was $318.25M, while the lowest revenue estimate was $303.09M, resulting in an average revenue estimate of $310.62M. In the same quarter a year ago, actual revenue was $43.47MBased on 7 analysts’ estimates, the company’s revenue will be $437.27M in the next fiscal year. The high estimate is $503M and the low estimate is $298.1M.
